Physician profile
Katherine S Mcclellan
NPI 1023544871
$7,250.11
in general payments reported to CMS, 2019-2025
40 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 92% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.26 · 2020: $112 · 2021: $1,985 · 2022: $1,504 · 2023: $937 · 2024: $1,007 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.69 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,476.18 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $706.22 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $687.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $675.42 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $598.03 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $533.50 | 2021-2025 | |
| Lilly USA, LLC | $309.71 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $270.58 | 2021-2023 | |
| Dexcom, INC. | $163.46 | 2024-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $157.78 | 2025 | Auvelity, Symbravo |
| Kowa Pharmaceuticals America, INC. | $156.29 | 2022-2025 | Zoryve, Seglentis |
| Sumitomo Pharma America, INC. | $142.76 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $131.48 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $117.07 | 2020-2025 | Gvoke Hypopen, Keveyis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.94 | 2020-2025 | Xifaxan |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mcclellan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.